Indutrade AB (publ)

Welcome and good morning on our behalf as well. We are quite happy with this quarter. It's good to be back in terms of organic growth and having a strong EBITDA margin. Let's start with some highlights. As I said, stable order intake, growth of 6% in total, where of 1% organically. Continued good demand in medical technology and pharmaceutical and also the process industry. It's basically the same segments and sectors as in quarter one. Net sales increased 5%, organically 1%, despite strong references and supported by some more working days.

margin of 14.8%, exactly the same as the underlying EBITDA margin last year. Inventory, slightly down from quarter one, 2024. And also a good acquisition pace, six acquisitions completed in quarter two and 12 so far in 2024. And the inflow of interesting companies to acquire remains strong. If we then comment a bit more on the order intake and savings, it's a continued aggregated stable high demand in terms of order intake and an increased invoicing pays versus the first quarter, resulting in record high 8.5 billion SEK. Both ordering taken as increase plus 1% organically versus high levels last And as I said, somewhat helped by more working . Total load intake and net sales increased with 6 percent and 5 percent respectively.

We still see some variations between segments and companies, and I will elaborate a bit more on this later. In terms of segments, the medtech and pharma sectors were good. In particular, we can mention that the diabetes area was good, both in terms of insulin production in the Danish solar market, but also device sales in the Scandinavian Nordic markets. And we also saw a good demand in the process industry more broadly there. As I've said before, we benefit or our companies benefit from the green transformation quite broadly in the Scandinavian area particularly, but quite a lot of projects also outside in the Western European sector or geography.